cas 944903-10-0|| where to buy 5-chloro-2-(piperidin-4-yl)pyrimidine

Nom du produit:5-chloro-2-(piperidin-4-yl)pyrimidine

IUPAC Name:5-chloro-2-(piperidin-4-yl)pyrimidine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM466825-1g	5-6 Weeks	ŮǪȃĲ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 944903-10-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:944903-10-0; Formule moléculaire:C9H12ClN3; Point de fusion:-; Code SMILES:ClC1=CN=C(N=C1)C1CCNCC1; Densité:

: Numéro de catalogue:CM466825; Poids moléculaire:197.67; Point d'ébullition:; N° Mdl:MFCD10697164; Stockage:

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Nerandomilast; Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.